4//SEC Filing
Kumar Neil 4
Accession 0001470831-25-000386
CIK 0001743881other
Filed
Dec 7, 7:00 PM ET
Accepted
Dec 8, 5:54 PM ET
Size
24.3 KB
Accession
0001470831-25-000386
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-12-04$73.16/sh−2,100$153,638→ 793,586 total(indirect: By Trust) - Sale
Common Stock
2025-12-04$74.42/sh−12,192$907,381→ 781,394 total(indirect: By Trust) - Sale
Common Stock
2025-12-04$74.80/sh−5,708$426,939→ 775,686 total(indirect: By Trust) - Sale
Common Stock
2025-12-05$73.05/sh−12,517$914,324→ 763,169 total(indirect: By Trust) - Sale
Common Stock
2025-12-05$73.76/sh−7,483$551,951→ 755,686 total(indirect: By Trust) - Sale
Common Stock
2025-12-04$74.42/sh−12,200$907,970→ 4,584,147 total(indirect: By Trust) - Sale
Common Stock
2025-12-04$74.80/sh−5,700$426,358→ 4,578,447 total(indirect: By Trust) - Sale
Common Stock
2025-12-05$73.04/sh−12,288$897,529→ 4,566,159 total(indirect: By Trust) - Sale
Common Stock
2025-12-05$73.75/sh−7,712$568,758→ 4,558,447 total(indirect: By Trust)
Holdings
- 228,776
Common Stock
Footnotes (10)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F10]Represents the weighted average sale price of the shares sold from $73.42 to $74.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F2]Represents the weighted average sale price of the shares sold from $72.71 to $73.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- [F4]Represents the weighted average sale price of the shares sold from $73.73 to $74.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $74.73 to $74.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]Represents the weighted average sale price of the shares sold from $72.46 to $73.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F7]Represents the weighted average sale price of the shares sold from $73.46 to $74.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F8]Represents the weighted average sale price of the shares sold from $72.71 to $73.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F9]Represents the weighted average sale price of the shares sold from $72.41 to $73.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Documents
Issuer
BridgeBio Pharma, Inc.
CIK 0001743881
Entity typeother
Related Parties
1- filerCIK 0001742485
Filing Metadata
- Form type
- 4
- Filed
- Dec 7, 7:00 PM ET
- Accepted
- Dec 8, 5:54 PM ET
- Size
- 24.3 KB